Presentation is loading. Please wait.

Presentation is loading. Please wait.

The microchip-based drug delivery device and overview of study design

Published byFausta Quarta Modified over 5 years ago

Similar presentations

Presentation on theme: "The microchip-based drug delivery device and overview of study design"— Presentation transcript:

1 Fig. 1 The microchip-based drug delivery device and overview of study design.
The microchip-based drug delivery device and overview of study design. (A and B) Microchip-based hPTH(1–34) drug delivery device (54 mm × 31 mm × 11 mm, l × w × h) (A) containing two microchips with 10 reservoirs each (13.0 mm × 5.4 mm × 0.5 mm, l × w × h) (B). (C) Schematic cross section of microchip assembly showing drug releasing from one reservoir. (D) Timeline of study events. Robert Farra et al., Sci Transl Med 2012;4:122ra21 Copyright © 2012, American Association for the Advancement of Science

Download ppt "The microchip-based drug delivery device and overview of study design"

Similar presentations

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Fig. 1. Distribution of TTNtv in healthy individuals and DCM patients, and TTN exon usage in the heart. Distribution of TTNtv in healthy individuals and.

Fig. 1. Distribution of TTNtv in healthy individuals and DCM patients, and TTN exon usage in the heart. Distribution of TTNtv in healthy individuals and.
Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Biocompatibility evaluation in vivo with a mouse subcutaneous implant
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.
Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.
In vivo release of doxycycline hyclate from the GRS in a swine model

In vivo release of doxycycline hyclate from the GRS in a swine model
Fig. 2 Fluidic and electrical characteristics of the wireless optofluidic system. Fluidic and electrical characteristics of the wireless optofluidic system.

Fig. 2 Fluidic and electrical characteristics of the wireless optofluidic system. Fluidic and electrical characteristics of the wireless optofluidic system.
Fig. 1 Wireless, battery-free neural cuff for programmable pharmacology and optogenetics. Wireless, battery-free neural cuff for programmable pharmacology.

Fig. 1 Wireless, battery-free neural cuff for programmable pharmacology and optogenetics. Wireless, battery-free neural cuff for programmable pharmacology.

Similar presentations

Ads by Google